PROFILPELAJAR.COM

Opipramol
(IUPAC) ime
	4-[3-(5H-dibenz[b,f]azepin- 5-yl)propyl]-1-piperazinethanol
Klinički podaci
Identifikatori
CAS broj	315-72-0
ATC kod	N06AA05
PubChem	9417
ChemSpider	9046
KEGG	D08297
ChEMBL	CHEMBL370753
Hemijski podaci
Formula	C23H29N3O
Mol. masa	363.496 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2 ; Key: YNZFUWZUGRBMHL-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	Oral

Opipramol (Insidon, Pramolan, Ensidon, Oprimol) je antidepresiv i anksiolitik koji se koristi u nizu Evropskih zemalja.^[6]^[7] Mada je on član porodice tricikličnih antidepresanata, primarni mehanizam dejstva se znatno razlikuje.^[7] On nije inhibitor preuzimanja nego deluje kao agonist sigma receptora, pored drugih osovina.^[7]

Indikacije

Opipramol se tipično koristi u lečenju generalizovanog anksioznog poremećaja.^[6] Njegovo dejstvo postaje uočljivo nakon 1-2 nedelje hronične upotrebe. Na početku primene, opipramol ima znatno sedativno dejstvo usled njegovih antihistaminskih osobina, ali taj efekat postaje manje promenentan sa vremenom.

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ ^6,0 ^6,1 Möller HJ, Volz HP, Reimann IW, Stoll KD (February 2001). „Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group”. Journal of Clinical Psychopharmacology 21 (1): 59–65. DOI:10.1097/00004714-200102000-00011. PMID 11199949.
↑ ^7,0 ^7,1 ^7,2 Müller WE, Siebert B, Holoubek G, Gentsch C (November 2004). „Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand”. Pharmacopsychiatry 37 Suppl 3: S189–97. DOI:10.1055/s-2004-832677. PMID 15547785.